Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
Background: Advances in Disease-Modifying Antirheumatic Drugs (DMARDs) have expanded the treatment landscape for Rheumatoid Arthritis (RA). Guidelines recommend adding either conventional synthetic (cs), biologic (b), or targeted synthetic (ts) DMARDs to methotrexate (MTX) for managing RA. Limited e...
Main Authors: | Yinan Huang, Satabdi Chatterjee, Sandeep K. Agarwal, Hua Chen, Michael L. Johnson, Rajender R. Aparasu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-09-01
|
Series: | Exploratory Research in Clinical and Social Pharmacy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S266727662300077X |
Similar Items
-
Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
by: Yinzhu Jin, et al.
Published: (2017-07-01) -
Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations
by: E L Nasonov
Published: (2016-12-01) -
METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS
by: E. L. Nasonov
Published: (2016-12-01) -
METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS
by: E. L. Nasonov
Published: (2015-09-01) -
METHOTREXATE IN RHEUMATOID ARTHRITIS – 2015: NEW FACTS AND IDEAS
by: E. L. Nasonov
Published: (2015-10-01)